Printer Friendly

PERSEPTIVE BIOSYSTEMS, INC. FILES REGISTRATION STATEMENT WITH SEC FOR PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK

 CAMBRIDGE, Mass., Feb. 11 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today that it has filed a registration statement with the Securities and Exchange Commission for a public offering of 2,000,000 shares of the Company's common stock. Managing underwriters for the offering are Alex. Brown & Sons Incorporated and Cowen & Company.
 All of the 2,000,000 shares of common stock are being sold by the Company. If the underwriters' over-allotment option is exercised, a current shareholder of the Company will sell up to an additional 300,000 shares of common stock.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The Company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 Prospectuses may be obtained from Alex. Brown & Sons Incorporated, 135 E. Baltimore Street, Baltimore, 21202, Attn: David DiPietro or Cowen & Company, Financial Square, 27th Floor, New York, 10005, Attn: Jack Dunphy.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not become effective. Information contained therein is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
 This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 -0- 2/11/93
 /CONTACT: Noubar B. Afeyan or Rob Fein, 617-621-1787 of PerSeptive Biosystems, Inc.;
 (PBIO)


CO: PerSeptive Biosystems ST: Massachusetts IN: MTC SU: OFR

TM -- NE002 -- 5510 02/11/93 08:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 11, 1993
Words:330
Previous Article:MALIBU COMICS' 'PROTECTORS NO. 5' TO FEATURE DEMISE OF SUPER-HERO 'NIGHT MASK'
Next Article:WOOLWORTH CORPORATION HAS NO PLANS TO SELL ITS GERMAN OPERATIONS
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES PUBLIC OFFERING OF TWO MILLION SHARES AT $18 PER SHARE
PERSEPTIVE BIOSYSTEMS ANNOUNCES ACQUISITION OF VESTEC CORPORATION
PERSEPTIVE BIOSYSTEMS REPORTS RESULTS FOR FIRST FISCAL QUARTER OF 1996
PERSEPTIVE BIOSYSTEMS' STOCKHOLDERS APPROVE ACQUISITION OF PERSEPTIVE TECHNOLOGIES II CORPORATION
PERSEPTIVE BIOSYSTEMS WINS PATENT DISPUTE
PerSeptive Biosystems, Inc. Announces Departure of Robert Anacone
PerSeptive Biosystems Reports Fourth Quarter Fiscal 1996 Results
PerSeptive Biosystems Appoints Hewlett-Packard Executive Don Schoeny Senior Vice President, Worldwide Sales, Service and Technical Support
PerSeptive Biosystems Reports Results for Second Fiscal Quarter of 1997; Product Sales up 20%; EPS of $1.02 Includes Gain from ChemGenics Merger

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters